537 related articles for article (PubMed ID: 24233489)
1. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation.
Chen Y; Ku H; Zhao L; Wheeler DC; Li LC; Li Q; Varghese Z; Moorhead JF; Powis SH; Huang A; Ruan XZ
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):365-76. PubMed ID: 24233489
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory stress reduces the effectiveness of statins in the kidney by disrupting HMGCoA reductase feedback regulation.
Chen Y; Zhao L; Li Q; Wheeler DC; Varghese Z; Moorhead JF; Powis SH; Ruan XZ
Nephrol Dial Transplant; 2014 Oct; 29(10):1864-78. PubMed ID: 24895437
[TBL] [Abstract][Full Text] [Related]
3. Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation.
Ma KL; Liu J; Wang CX; Ni J; Zhang Y; Wu Y; Lv LL; Ruan XZ; Liu BC
Cardiovasc Res; 2013 Dec; 100(3):450-60. PubMed ID: 24068000
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory stress exacerbates lipid-mediated renal injury in ApoE/CD36/SRA triple knockout mice.
Xu ZE; Chen Y; Huang A; Varghese Z; Moorhead JF; Yan F; Powis SH; Li Q; Ruan XZ
Am J Physiol Renal Physiol; 2011 Oct; 301(4):F713-22. PubMed ID: 21795641
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
[TBL] [Abstract][Full Text] [Related]
6. Tissue-specific effects of atorvastatin on 3-hydroxy-3-methylglutarylcoenzyme A reductase expression and activity in spontaneously hypertensive rats.
Chen GP; Yao L; Lu X; Li L; Hu SJ
Acta Pharmacol Sin; 2008 Oct; 29(10):1181-6. PubMed ID: 18817622
[TBL] [Abstract][Full Text] [Related]
7. Sepsis syndrome stimulates proximal tubule cholesterol synthesis and suppresses the SR-B1 cholesterol transporter.
Zager RA; Johnson AC; Hanson SY
Kidney Int; 2003 Jan; 63(1):123-33. PubMed ID: 12472775
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory cytokines disrupt LDL-receptor feedback regulation and cause statin resistance: a comparative study in human hepatic cells and mesangial cells.
Chen Y; Ruan XZ; Li Q; Huang A; Moorhead JF; Powis SH; Varghese Z
Am J Physiol Renal Physiol; 2007 Sep; 293(3):F680-7. PubMed ID: 17634396
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor Atorvastatin and hepatic LRP1 expression.
Moon JH; Kang SB; Park JS; Lee BW; Kang ES; Ahn CW; Lee HC; Cha BS
Metabolism; 2011 Jul; 60(7):930-40. PubMed ID: 20951395
[TBL] [Abstract][Full Text] [Related]
10. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators.
Kizu A; Shioi A; Jono S; Koyama H; Okuno Y; Nishizawa Y
J Cell Biochem; 2004 Nov; 93(5):1011-9. PubMed ID: 15389884
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin inhibits inflammatory hypernociception.
Santodomingo-Garzón T; Cunha TM; Verri WA; Valério DA; Parada CA; Poole S; Ferreira SH; Cunha FQ
Br J Pharmacol; 2006 Sep; 149(1):14-22. PubMed ID: 16865092
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Ajamieh H; Farrell G; Wong HJ; Yu J; Chu E; Chen J; Teoh N
J Gastroenterol Hepatol; 2012 Aug; 27(8):1353-61. PubMed ID: 22432744
[TBL] [Abstract][Full Text] [Related]
13. Statins have biphasic effects on angiogenesis.
Weis M; Heeschen C; Glassford AJ; Cooke JP
Circulation; 2002 Feb; 105(6):739-45. PubMed ID: 11839631
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm.
Li Y; Lu G; Sun D; Zuo H; Wang DW; Yan J
PLoS One; 2017; 12(4):e0174821. PubMed ID: 28369137
[TBL] [Abstract][Full Text] [Related]
15. Scavenger receptor CD36 mediates inhibition of cholesterol synthesis via activation of the PPARγ/PGC-1α pathway and Insig1/2 expression in hepatocytes.
Rodrigue-Way A; Caron V; Bilodeau S; Keil S; Hassan M; Lévy E; Mitchell GA; Tremblay A
FASEB J; 2014 Apr; 28(4):1910-23. PubMed ID: 24371122
[TBL] [Abstract][Full Text] [Related]
16. Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.
Rodríguez-Vita J; Sánchez-Galán E; Santamaría B; Sánchez-López E; Rodrigues-Díez R; Blanco-Colio LM; Egido J; Ortiz A; Ruiz-Ortega M
PLoS One; 2008; 3(12):e3959. PubMed ID: 19088845
[TBL] [Abstract][Full Text] [Related]
17. Hydroxymethylglutaryl coenzyme A reductase inhibition reduces Chlamydia pneumoniae-induced cell interaction and activation.
Dechend R; Gieffers J; Dietz R; Joerres A; Rupp J; Luft FC; Maass M
Circulation; 2003 Jul; 108(3):261-5. PubMed ID: 12860900
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
[TBL] [Abstract][Full Text] [Related]
19. Statins normalize vascular lysyl oxidase down-regulation induced by proatherogenic risk factors.
Rodríguez C; Alcudia JF; Martínez-González J; Guadall A; Raposo B; Sánchez-Gómez S; Badimon L
Cardiovasc Res; 2009 Aug; 83(3):595-603. PubMed ID: 19406911
[TBL] [Abstract][Full Text] [Related]
20. Does atorvastatin induce aortic smooth muscle cell apoptosis in vivo?
Doyon M; Hale TM; Huot-Marchand JE; Wu R; de Champlain J; DeBlois D
Vascul Pharmacol; 2011; 54(1-2):5-12. PubMed ID: 20951229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
